3 Top Growth Stocks to Buy in the First Half of 2026

Meta is positioned to monetize AI-enabled Ray-Ban display glasses while its advertising franchise remains the primary value driver, with 3.54 billion daily users in September 2025 (up 8% YoY, ~43% of global population). Micron trades at a forward P/E of 10.8 and a PEG of 0.6 despite strong demand dynamics: its fiscal 2026 full HBM supply is already allocated, management forecasts HBM TAM CAGR ~40% through 2028 and ~20% shipment growth for DRAM and NAND in 2026. Small-cap Mirum (market cap ~$4.5bn) posted a 91% share gain in 2025, saw Livmarli sales of $92.2m in Q3 2025 (+56% YoY), and has several 2026 catalysts including Q2 voloxibat PSC data, a potential H2 U.S. filing, and the pending Bluejay acquisition with a phase‑3 readout for brelovitug later in the year.

Analysis

Market structure: META, MU and event-driven small-cap biotech MIRM are the direct beneficiaries. META’s 3.54bn DAUs (up 8% YoY) sustains ad pricing power while Ray‑Ban AI glasses create optionality over 12–24 months; MU benefits from an HBM TAM growing ~40% CAGR to 2028 and management’s view of a multi‑year supply shortfall with HBM fully allocated for FY26 and ~20% DRAM/NAND shipment growth in 2026, tightening pricing. Incumbent commodity memory suppliers with weak HBM exposure lose share and margin.

Risk assessment: Key tail risks are regulatory/antitrust action or privacy restrictions for META (timeline 6–24 months), a sudden hyperscaler capex pause that materially reduces HBM demand (quarterly shock), and binary clinical failures at MIRM (Q2 2026 voloxibat readout; Bluejay Phase 3 later in 2026). Hidden dependencies include packaging/fab bottlenecks for HBM and hyperscaler architecture shifts (e.g., model memory efficiency) that could collapse demand; monitor quarterly HBM allocation disclosures and hyperscaler order cadence.

Trade implications: Favor overweight in AI memory and core ad platforms: establish MU position (target 3–5% portfolio) and a smaller META overweight (2–4%) with disciplined hedges; take micro‑caps like MIRM as event‑driven stakes (1–2%) ahead of Q2 readouts. Use options to define risk: MU buy-call spreads into earnings and MIRM buy-call spreads timed to post‑readout expiries; sell OTM calls on 25% of META exposure to finance long‑duration LEAPs.

Contrarian angles: Consensus underprices structural HBM scarcity (PEG 0.6, MU forward P/E 10.8 suggests mispricing) but may overvalue near‑term optics of AI glasses as a revenue driver for META — real upside is ad ARPU, not hardware. Historical DRAM cycles show outsized rallies followed by demand destruction; set stop‑loss triggers (see decisions) to avoid being caught by cyclic inventory resets.

Key Decisions for Investors

• Establish a 3–5% portfolio long position in MU over the next 2–6 weeks (scale in 25% tranches). Hedge with a 6‑month 15–20% OTM put or buy a 6‑month call spread (e.g., buy 0–+25% strike spread) to limit downside; target 30–50% upside within 12–18 months if HBM tightness persists.
• Add a 2–4% overweight in META for a 12–24 month hold, funded by trimming 25% of lower conviction names. Finance 12–18 month upside with selling 3‑month 30% OTM calls on 25% of the new position; add on >10% pullbacks and trim if ad revenue growth slows below +5% YoY quarter.
• Initiate a risk‑managed event trade in MIRM at 1–2% portfolio weight before Q2 2026 voloxibat readout and Bluejay close: buy Jul–Sep 2026 call spreads to cap premium (e.g., ATM to +30% strikes). Take profits: sell half on a >40% pop post‑readout or cut to zero on trial miss.
• Rotate +3% weight from lower‑conviction consumer discretionary into semiconductor hardware (MU and select suppliers) over 3 months. Stop‑loss / re‑assessment triggers: reduce MU if guidance shows DRAM/NAND shipment growth <10% or if HBM allocation falls below 75% of FY26 projected volume; exit MIRM on primary endpoint failure.